Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
ON 01910.Na has undergone preclinical and clinical phase I studies showing activity in
patients with progressing ovarian cancer resistant to platinum-based chemotherapies. This
study will look at a larger population of patients to determine whether treatment with ON
01910.Na has an effect on progression free survival rates in patients with platinum-resistant
ovarian cancer. ON 01910.Na will be given as an intravenous infusion over 2 hours on days 1,
4, 8, 11, 15, and 18 of a 28-day cycle. Patients will be treated for 6 or more cycles.